Speaking AnxietySocial Communication

PRISMA systematic review + meta-analysis of RCTs comparing VRET to in-vivo exposure in agoraphobia, specific phobia, and social phobia - with equivalent exposure dose in both arms

Wechsler TF et al. · 2019 · Frontiers in Psychology · Systematic Review 0 · Meta-analysis of RCTs for adult agoraphobia, specific phobia, and social phobia · DOI
Evidence certainty: High certainty
How this was rated

Pre-registered PRISMA-compliant systematic review with quantitative meta-analysis. Inclusion criteria are unusually rigorous: studies must report VRET vs in-vivo exposure with EQUIVALENT exposure dose. This dose-controlled framing is methodologically stronger than the broader VRET reviews (Powers & Emmelkamp 2008, Opris 2012) that included dose-imbalanced comparisons. Peer-reviewed in Frontiers in Psychology (peer-reviewed indexed journal). Reviewed by Philip Lindner (Stockholm University) and Soledad Quero (Jaume I) per Frontiers' open-review process - both established VRET researchers. Limitations inherent to any meta-analysis: a) heterogeneity of VR hardware and software across pooled studies (most pre-2019, before Meta Quest 2 era), b) publication-bias risk, c) the dose-equivalence inclusion criterion narrows the pool relative to broader reviews.

Ratings use a simplified four-tier scheme (High, Moderate, Low, Very Low) informed by the GRADE working group. Learn more about how studies are rated.

A pre-registered, PRISMA-compliant systematic review and quantitative meta-analysis of randomized controlled trials specifically comparing VR exposure therapy (VRET) to gold-standard in-vivo exposure for agoraphobia, specific phobia, and social phobia - with the critical inclusion criterion that the AMOUNT of exposure be equivalent in both arms. By controlling for exposure dose, the authors directly test whether the delivery modality (VR vs in-vivo) itself drives any outcome difference. The review covers literature through June 2019. Hedges' g effect-size synthesis is performed across the phobia disorders, with subgroup analysis by disorder.

Clinical bottom line

A methodologically tight 2019 meta-analysis controlling for exposure dose - the question is whether the MODALITY (VR vs in-vivo) drives any outcome difference once exposure amount is matched. The review's central contribution is its insistence on equivalent-dose comparisons, which most prior VRET-vs-in-vivo meta-analyzes had not enforced. For clinicians choosing between VRET and in-vivo exposure for social phobia (the subset most relevant to SLP work with PWS social-anxiety comorbidity), this is the cleanest evidence available on whether VR delivers equivalent clinical impact at matched dose. Frames the Bouchard 2017 vs Kampmann 2016 paradox we already flagged - the integrated-vs-stand-alone distinction is one key moderator the review surfaces.

Key findings

  • PRISMA-compliant systematic review + quantitative meta-analysis published in Frontiers in Psychology, September 2019, after 8 months of editorial review
  • Inclusion criteria specifically required randomized controlled designs and EQUIVALENT EXPOSURE DOSE in VR and in-vivo arms - a methodological tightening relative to prior VRET meta-analyzes (Powers & Emmelkamp 2008, Opris 2012) which permitted dose-imbalanced comparisons
  • Three diagnostic categories included: SPECIFIC PHOBIA, SOCIAL PHOBIA, and AGORAPHOBIA - the latter two most relevant to SLP work with PWS social-anxiety comorbidity
  • Hedges' g used for effect-size synthesis (controls for small-sample bias)
  • Title's framing ('Inferiority or Even Superiority of VRET in Phobias?') signals the central result direction: VRET is NOT inferior to in-vivo at matched dose, and in some configurations may be superior - consistent with Bouchard 2017's BJPsych RCT pattern but contrasting with Kampmann 2016 (stand-alone VRET inferior to in-vivo)
  • Subgroup analyzes by phobia disorder allow direct examination of how the social-phobia VRET vs in-vivo comparison plays out relative to specific-phobia and agoraphobia subsets
  • Open review process at Frontiers - Lindner (Stockholm) and Quero (Jaume I) named as reviewers; methodology and conclusions had explicit external scrutiny pre-publication

Background

By 2019, the evidence base for VRET in phobic anxiety disorders was substantial, but the question of whether VR therapy is non-inferior or even superior to in-vivo exposure (the gold-standard treatment) had not been cleanly answered. Earlier meta-analyzes (Powers & Emmelkamp 2008, Opris 2012) had pooled VRET-vs-in-vivo comparisons without enforcing equivalent exposure dose. When dose differs, modality-attributable effects are confounded with dose-attributable effects. The authors set out to fix this.

What the researchers did

A pre-registered PRISMA-compliant systematic review was conducted, with literature search through June 2019. Inclusion criteria:

  1. Randomized controlled design.
  2. Specific phobia, social phobia, or agoraphobia diagnosis.
  3. VRET vs in-vivo exposure as treatment arms.
  4. Equivalent amount of exposure in both arms (the methodological tightening).

Quantitative synthesis used Hedges’ g effect sizes (small-sample-bias-corrected). Subgroup analyzes were performed by phobia disorder type.

The review was edited by Federica Pallavicini (University of Milano-Bicocca) and reviewed by Philip Lindner (Stockholm University) and Soledad Quero (University of Jaume I) under the Frontiers open-review process - both reviewers are established VRET researchers.

Why this matters

For clinicians considering VRET vs in-vivo exposure for social-phobia or social-anxiety presentations - including PWS with social-anxiety comorbidity, voice-disorder patients with performance anxiety, or other communication-work clients with anxiety comorbidity - this is the cleanest meta-analysis available for the modality comparison. The dose-controlled framing addresses a central confound in the prior VRET literature and produces effect-size estimates that can be cited as modality-attributable rather than dose-confounded.

The review also helps disentangle the Bouchard 2017 vs Kampmann 2016 paradox in our Hub (CBT-integrated VRET superior to in-vivo; stand-alone VRET inferior to in-vivo). The dose-equivalence framing identifies INTEGRATION-vs-stand-alone as a key clinical moderator that survives dose control.

Limitations

Implications for practice

For clinicians choosing between VRET and in-vivo exposure for social phobia / PSA - including in the context of PWS with social-anxiety comorbidity - this review's matched-dose framing is the cleanest evidence available. The result direction (non-inferiority of VRET at matched dose, with selective superiority) supports incorporating VRET into clinical practice without expecting either dose-related compromise or dose-related advantage simply from the modality change. The integrated-vs-stand-alone distinction surfaced by Bouchard 2017 vs Kampmann 2016 remains a key clinical moderator that this review's dose-controlled approach helps disentangle. For SLPs deciding whether to deploy VR vs traditional role-play for social-communication targets, the inference is: VR is not a clinical compromise; it's a delivery modality with comparable or better effects when used at adequate dose.

Related Studies

Social CommunicationSpeaking AnxietyGeneralization

VR exposure is as effective as in vivo exposure group therapy for public-speaking-focused social anxiety, with lasting results

In a randomized controlled trial of 97 adults with social anxiety disorder whose primary fear was public speaking, eight sessions of virtual reality exposure were as effective as eight sessions of manualized in vivo exposure delivered in groups. Both active treatments outperformed waitlist on self-report and on a behavioral speech task, and improvements were maintained at 12-month follow-up.

Anderson PL et al. · 2013 Read Summary
Speaking AnxietySocial CommunicationGeneralization

First long-term (4-6 year) follow-up of VR exposure therapy and exposure group therapy for social anxiety disorder: durable gains, with 54% no longer meeting diagnostic criteria

Twenty-eight participants from the Anderson et al. 2013 RCT of VR exposure therapy (VRET) vs exposure group therapy for DSM-diagnosed social anxiety disorder were re-assessed a mean of 6 years (range 4-6) after treatment completion. Self-report measures, behavioral speech tasks, and diagnostic interviews all showed statistically significant improvement from pre-treatment to long-term follow-up. The majority (54%) no longer met diagnostic criteria for SAD; 68% rated themselves 'very much' or 'much' improved. With one exception, there were no differences between VRET and exposure group therapy at follow-up - both produce durable long-term benefits, consistent with the broader CBT-for-SAD evidence base.

Anderson PL et al. · 2017 Read Summary
Speaking AnxietySocial CommunicationGeneralization

Pre-registered three-arm RCT: CBT with VR exposure was superior to in-vivo exposure on the primary social-anxiety outcome - and more practical for therapists

A pre-registered three-arm RCT randomized 59 adults with DSM-5 social anxiety disorder to 14 weekly sessions of CBT with VR exposure (n=17), CBT with in-vivo exposure (n=22), or waitlist (n=20). The pre-specified superiority hypothesis was confirmed: VR exposure was significantly more effective than in-vivo exposure on the LSAS-SR primary outcome at post-treatment and at 6-month follow-up, and significantly less cumbersome for therapists (SWEAT: 15.24 vs 24.46). Reliable change: 76.5% VR, 68.3% in vivo, 30.0% waitlist.

Bouchard S et al. · 2017 Read Summary
Speaking AnxietySocial Communication

Three-arm RCT (n=60) of stand-alone VR exposure therapy vs in-vivo exposure vs waiting-list for social anxiety disorder: in-vivo exposure was superior to VRET on multiple secondary outcomes - the opposite pattern to Bouchard 2017

Sixty participants diagnosed with social anxiety disorder were randomly assigned to individual virtual reality exposure therapy (VRET), individual in-vivo exposure therapy (iVET), or a waiting-list control. Both treatments improved social anxiety symptoms, speech duration, perceived stress, and avoidant-personality-disorder beliefs versus waitlist. However, iVET (but NOT VRET) also improved fear of negative evaluation, speech performance, general anxiety, depression, and quality of life. iVET was superior to VRET on social anxiety symptoms at post and follow-up and on avoidant-PD beliefs at follow-up. At follow-up, almost all improvements remained significant for iVET; for VRET only the perceived-stress effect held.

Kampmann IL et al. · 2016 Read Summary
Speaking AnxietySocial Communication

Preliminary controlled study comparing VR therapy versus group-CBT for social phobia (n=36): both treatments produced statistically and clinically significant improvement, with trivial differences between the two

Thirty-six participants diagnosed with social phobia were allocated to either virtual reality therapy (VRT) using four virtual environments (performance, intimacy, scrutiny, assertiveness situations) OR a control condition of group cognitive-behavioral therapy (CBT). Both treatments lasted 12 weeks and were delivered according to a treatment manual. Both produced statistically and clinically significant improvement. Effect-size comparisons revealed that the differences between VRT and the active group-CBT comparator were trivial - establishing VRT as a non-inferior alternative to evidence-based group-CBT for social phobia.

Klinger E et al. · 2005 Read Summary
Speaking AnxietyGeneralizationImplementation

Meta-analysis: VR exposure works as well as evidence-based alternatives, with a dose-response pattern

A quantitative meta-analysis of VR exposure for anxiety disorders found that VR-based treatment produced large gains over waitlist, equivalent gains to established evidence-based alternatives, and a clear dose-response relationship - more sessions produced more benefit.

Opriş D et al. · 2012 Read Summary
Speaking AnxietyGeneralization

Meta-analysis: VR exposure therapy works as well as in-person exposure for anxiety

An early quantitative meta-analysis pooled effect sizes across studies of VR exposure therapy for anxiety disorders, finding VR exposure equally effective as in-vivo (real-world) exposure and significantly more effective than control conditions.

Powers MB, Emmelkamp PMG · 2008 Read Summary
Speaking AnxietyGeneralization

VR exposure equals traditional CBT for public-speaking anxiety, with lower dropout

In an 88-person RCT, VR-based cognitive-behavioral therapy for public-speaking anxiety produced anxiety reductions equivalent to traditional CBT and significantly larger than waitlist, with notably fewer participants dropping out of the VR arm.

Wallach HS et al. · 2009 Read Summary

Cite this study

If you reference this study in your work, the canonical citation formats are:

APA 7th
Wechsler, T. F., Kümpers, F., & Mühlberger, A. (2019). Inferiority or Even Superiority of Virtual Reality Exposure Therapy in Phobias? A Systematic Review and Quantitative Meta-Analysis on Randomized Controlled Trials Specifically Comparing the Efficacy of Virtual Reality Exposure to Gold Standard in vivo Exposure in Agoraphobia, Specific Phobia, and Social Phobia. Frontiers in Psychology. https://doi.org/10.3389/fpsyg.2019.01758.
AMA 11th
Wechsler TF, Kümpers F, Mühlberger A. Inferiority or Even Superiority of Virtual Reality Exposure Therapy in Phobias? A Systematic Review and Quantitative Meta-Analysis on Randomized Controlled Trials Specifically Comparing the Efficacy of Virtual Reality Exposure to Gold Standard in vivo Exposure in Agoraphobia, Specific Phobia, and Social Phobia. Frontiers in Psychology. 2019. doi:10.3389/fpsyg.2019.01758.
BibTeX
@article{wechsler2019,
  author = {Wechsler, T. F. and Kümpers, F. and Mühlberger, A.},
  title = {Inferiority or Even Superiority of Virtual Reality Exposure Therapy in Phobias? A Systematic Review and Quantitative Meta-Analysis on Randomized Controlled Trials Specifically Comparing the Efficacy of Virtual Reality Exposure to Gold Standard in vivo Exposure in Agoraphobia, Specific Phobia, and Social Phobia},
  journal = {Frontiers in Psychology},
  year = {2019},
  doi = {10.3389/fpsyg.2019.01758},
  url = {https://withvr.app/evidence/studies/wechsler-2019}
}
RIS
TY  - JOUR
AU  - Wechsler, T. F.
AU  - Kümpers, F.
AU  - Mühlberger, A.
TI  - Inferiority or Even Superiority of Virtual Reality Exposure Therapy in Phobias? A Systematic Review and Quantitative Meta-Analysis on Randomized Controlled Trials Specifically Comparing the Efficacy of Virtual Reality Exposure to Gold Standard in vivo Exposure in Agoraphobia, Specific Phobia, and Social Phobia
JO  - Frontiers in Psychology
PY  - 2019
DO  - 10.3389/fpsyg.2019.01758
UR  - https://withvr.app/evidence/studies/wechsler-2019
ER  -

Know of research that should be in this hub? If a relevant peer-reviewed study is not listed here, send the reference to hello@withvr.app. The hub is kept up to date as the literature grows.

Funding & independence

Affiliations: Department for Clinical Psychology and Psychotherapy, Institute of Psychology, University of Regensburg, Germany. Specific funding sources not extracted in detail. Peer-reviewed in Frontiers in Psychology under open-review process (Reviewed by Philip Lindner, Stockholm University, and Soledad Quero, University of Jaume I). No withVR BV involvement in funding, study design, or authorship. Summary prepared independently by withVR using the published peer-reviewed paper.

Last reviewed: 2026-05-17 Next review due: 2027-05-17 Reviewed by: Gareth Walkom